fluconazole has been researched along with clinafloxacin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Damu, GL; Geng, RX; Lv, JS; Wang, Y; Yang, DC; Zhou, CH | 1 |
| Chang, JJ; Damu, GL; Geng, RX; Zhang, L; Zhang, SL; Zhou, CH | 1 |
| Geng, RX; Kumar, KV; Zhang, L; Zhou, CH | 1 |
| Addla, D; Cai, GX; Geng, RX; Li, S; Ponmani, J; Wang, A; Wang, YN; Xie, D; Zhang, L; Zhang, SL; Zhou, CH | 1 |
| Ba, Y; Hou, X; Wang, S; Xu, Z; Yang, H; Zhang, J | 1 |
1 review(s) available for fluconazole and clinafloxacin
| Article | Year |
|---|---|
Nitroimidazole-containing compounds and their antibacterial and antitubercular activities.
Topics: Anti-Bacterial Agents; Bacterial Infections; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Molecular Structure; Nitroimidazoles | 2019 |
9 other study(ies) available for fluconazole and clinafloxacin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacterial Infections; Drug Design; Fluoroquinolones; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycoses; Staphylococcal Infections; Triazoles | 2012 |
Synthesis and bioactive evaluation of novel hybrids of metronidazole and berberine as new type of antimicrobial agents and their transportation behavior by human serum albumin.
Topics: Anti-Infective Agents; Bacteria; Berberine; Binding Sites; Biological Transport; Fungi; Humans; Magnetic Resonance Spectroscopy; Metronidazole; Molecular Structure; Serum Albumin; Thermodynamics | 2013 |
Design and biological evaluation of novel quinolone-based metronidazole derivatives as potent Cu(2+) mediated DNA-targeting antibacterial agents.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Chemistry Techniques, Synthetic; Ciprofloxacin; Copper; DNA, Bacterial; Drug Evaluation, Preclinical; Fibroblasts; Fluoroquinolones; HEK293 Cells; Humans; Metronidazole; Mice; Microbial Sensitivity Tests; Molecular Targeted Therapy; Norfloxacin; Pseudomonas aeruginosa; Quinolones; Structure-Activity Relationship | 2015 |
Discovery of membrane active benzimidazole quinolones-based topoisomerase inhibitors as potential DNA-binding antimicrobial agents.
Topics: Anti-Bacterial Agents; Benzimidazoles; Binding Sites; DNA, Bacterial; Dose-Response Relationship, Drug; Drug Discovery; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Molecular Structure; Quinolones; Structure-Activity Relationship; Topoisomerase Inhibitors | 2016 |